Thomas J. Schaefer

CIK: 0001960808

Transaction Breakdown

Open Market Buys (P)1 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RKDA

Arcadia Biosciences, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

RKDA
Arcadia Biosciences, Inc.
May 9, 2025
Award(A)
Stock Option (Right to Buy)
Direct
12.5K shares-
RKDA
Arcadia Biosciences, Inc.
Feb 3, 2025
Purchase(P)
Direct
700 shares at avg. $2.49$2K

		Type	Shares	Price		Ownership
May 9, 2025	RKDA Arcadia Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	12,500	-	-	Direct
Feb 3, 2025	RKDA Arcadia Biosciences, Inc.	Purchase(P)	700	$2.49	$1,743	Direct

1-2 of 2 transactions

About Schaefer Thomas J.

Schaefer Thomas J. (SEC CIK 0001960808) files insider reports with the SEC as Chief Executive Officer of Arcadia Biosciences, Inc. (RKDA).

Signal8 holds 2 ownership filings by Schaefer Thomas J., all Form 4s, filed between Feb 5, 2025 and May 12, 2025. Those filings report 2 transactions, from Feb 3, 2025 to May 9, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Schaefer Thomas J.'s filings is in DALLAS, TX.

Recent filings by Schaefer Thomas J.

May 9, 2025: Grant or award of RKDA derivative securities (Form 4, code A).
Feb 3, 2025: Open-market purchase of RKDA shares (Form 4, code P).

Other insiders filing for Arcadia Biosciences, Inc. (RKDA)

Yoder Amy, Director
Comcowich Kevin, Director
WALLER GREGORY D, Director
Murray Lilian Shackelford, Director
Kawakami Mark, Chief Financial Officer

How to read Form 4 transaction codes